Goldman likes that the company posted solid earnings last year and, in addition to Valrox, is developing a treatment for achondroplasia, which causes dwarfism.Another factor might be built into Goldman's price objective: the chance that BioMarin could be acquired, with Roche (RHHBY) mentioned as a likely suitor.